Cargando…
Tolerability of ORM-12741 and effects on episodic memory in patients with Alzheimer's disease
INTRODUCTION: ORM-12741 is a novel selective antagonist of alpha-2C adrenoceptors. This trial evaluated the safety and efficacy of ORM-12741 in patients with Alzheimer's disease (AD). METHODS: A randomized, double-blind, placebo-controlled, exploratory phase 2a trial was conducted in 100 subjec...
Autores principales: | Rinne, Juha O., Wesnes, Keith, Cummings, Jeffrey L., Hakulinen, Pasi, Hallikainen, Merja, Hänninen, Jutta, Murphy, Michael, Riordan, Henry, Scheinin, Mika, Soininen, Hilkka, Rouru, Juha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651366/ https://www.ncbi.nlm.nih.gov/pubmed/29067315 http://dx.doi.org/10.1016/j.trci.2016.11.004 |
Ejemplares similares
-
Application of the PET ligand [(11)C]ORM-13070 to examine receptor occupancy by the α(2C)-adrenoceptor antagonist ORM-12741: translational validation of target engagement in rat and human brain
por: Shahid, Mohammed, et al.
Publicado: (2020) -
Imaging of α2C-adrenoceptors in the living brain: a method to monitor noradrenaline release?
por: Scheinin, Mika, et al.
Publicado: (2015) -
Thalamic Atrophy Without Whole Brain Atrophy Is Associated With Absence of 2-Year NEDA in Multiple Sclerosis
por: Hänninen, Katariina, et al.
Publicado: (2019) -
Thalamic Atrophy Predicts 5-Year Disability Progression in Multiple Sclerosis
por: Hänninen, Katariina, et al.
Publicado: (2020) -
Persistence in PHP with the doctrine ORM
por: Dunglas, Kévin
Publicado: (2013)